The Clinical Cost of Delays in Switching Therapy
Management of the HIV patient with treatment experience continues to improve and evolve. New guidelines suggest that the goal of therapy should be maximal virological suppression. This is best achieved by using combinations of agents to which the virus is most likely to have some susceptibility and,...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2007-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2007/761872 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560910205452288 |
|---|---|
| author | Sharon Walmsley |
| author_facet | Sharon Walmsley |
| author_sort | Sharon Walmsley |
| collection | DOAJ |
| description | Management of the HIV patient with treatment experience continues to improve and evolve. New guidelines suggest that the goal of therapy should be maximal virological suppression. This is best achieved by using combinations of agents to which the virus is most likely to have some susceptibility and, where possible, by using agents within a new therapeutic class. The cases discussed demonstrate how the use of a potent regimen as salvage therapy can have good clinical, immunological and virological outcomes. However, if the salvage regimen selected is not potent enough to achieve these goals, the durability of the response is limited. The key lesson is that these strategies should be built on potency and agents should not be held back in case the strategy fails. |
| format | Article |
| id | doaj-art-e7d7b3a3ebdf4534a4e2e3cb098c244f |
| institution | Kabale University |
| issn | 1712-9532 |
| language | English |
| publishDate | 2007-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-e7d7b3a3ebdf4534a4e2e3cb098c244f2025-02-03T01:26:25ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322007-01-0118Suppl A5A7A10.1155/2007/761872The Clinical Cost of Delays in Switching TherapySharon Walmsley0Division of Infectious Diseases, Department of Medicine, University of Toronto, and Toronto General Hospital, Toronto, Ontario, CanadaManagement of the HIV patient with treatment experience continues to improve and evolve. New guidelines suggest that the goal of therapy should be maximal virological suppression. This is best achieved by using combinations of agents to which the virus is most likely to have some susceptibility and, where possible, by using agents within a new therapeutic class. The cases discussed demonstrate how the use of a potent regimen as salvage therapy can have good clinical, immunological and virological outcomes. However, if the salvage regimen selected is not potent enough to achieve these goals, the durability of the response is limited. The key lesson is that these strategies should be built on potency and agents should not be held back in case the strategy fails.http://dx.doi.org/10.1155/2007/761872 |
| spellingShingle | Sharon Walmsley The Clinical Cost of Delays in Switching Therapy Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | The Clinical Cost of Delays in Switching Therapy |
| title_full | The Clinical Cost of Delays in Switching Therapy |
| title_fullStr | The Clinical Cost of Delays in Switching Therapy |
| title_full_unstemmed | The Clinical Cost of Delays in Switching Therapy |
| title_short | The Clinical Cost of Delays in Switching Therapy |
| title_sort | clinical cost of delays in switching therapy |
| url | http://dx.doi.org/10.1155/2007/761872 |
| work_keys_str_mv | AT sharonwalmsley theclinicalcostofdelaysinswitchingtherapy AT sharonwalmsley clinicalcostofdelaysinswitchingtherapy |